DoW-Funded Phase 2a Trial for BioXcel's BXCL501 in Acute Stress Reactions Begins Enrollment
BTAI is trading near its 52-week low of $1.06 (10% above the low).
Summary
BioXcel Therapeutics announced the enrollment of the first patients in a U.S. Department of War (DoW)-funded Phase 2a clinical trial for BXCL501 (sublingual dexmedetomidine) to treat acute stress reactions (ASR). This development is a significant positive for the micro-cap biopharmaceutical company, as it advances BXCL501 into a new, potentially substantial indication with the financial backing of the DoW, reducing the company's trial costs. BXCL501 is already approved for agitation, and success in this trial could expand its market significantly and potentially influence VA/DoW Clinical Practice Guidelines for ASR management. Investors will now watch for further updates on trial progress and eventual data readouts as key future catalysts.
At the time of this announcement, BTAI was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.5M. The 52-week trading range was $1.06 to $8.08. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.